Marshall on Oncology

- No-Visitor Policies Are Bad Medicine
124
- COVID-19 Has Strengthened Pharma's Negotiating Hand
5
- Practice-Changing GI Cancer Highlights From Virtual ASCO 2020
- Taking a Break From the Medical 'Service Industry'
4
- Molecular Profiling Is Key to GI Cancer Treatment Success
- Hype, Fear of Failure Driving Immunotherapy 'Hail Mary' Treatments
- Practice-Changing Regorafenib Data at 2018 GI Cancers Symposium
2
- Celebrating the End of Chemo Can Isolate Those Not So Lucky
2
- New GI Cancer Studies: Curious Failures, Hidden Gems
1
- Clinical Trials Are 'Too Damn Complicated'
9
- Will Adjuvant Oxaliplatin Data Change Practice in CRC?
- Mud Pies: Superfood for the Microbiome?
17
- 12 Chemo Cycles: More Toxicity Than Therapy?
7
- 'Can Do' Collaborations Speed Progress in GI Cancers
2
- HER2+ Colorectal Cancer: Slicing the Pie Into Curable Portions
1
- CRC Builds Up STEAM in Midst of Blizzard
1
- Can Physicians Help Heal the Body Politic?
- Is Chemo Needed in Patients With MSI Colon Cancer?
7
- ASCO 2015 Raises the Question of Value
2
- Waves of Emotion, Understanding After PBS Cancer
5